Surveillance for rare disorders by the BPSU

C Verity, M Preece

Why is it worthwhile?

The basic idea behind the Unit is simple enough. Investigators who want to perform surveillance studies apply to the BPSU Executive Committee for places on the BPSU surveillance card. Each month the BPSU office sends the orange surveillance card to over 2000 consultant paediatricians in the United Kingdom and Ireland. The card lists the disorders currently under surveillance. If a child with one of these disorders has been seen during the previous month, the local paediatrician is asked to tick the appropriate box on the card and return it to the BPSU office. The office then tells the relevant surveillance group so that the paediatrician can be contacted to obtain the clinical details, usually by questionnaire. Data about patients are held securely by the surveillance groups and no information about individual patients is held by the BPSU.

HOW DOES THE BPSU WORK?

The BPSU has provided data to help decide whether or not to perform national screening programmes for congenital infections. It was found that there were sufficient numbers of cases of transmissible syphilis and of congenital rubella to justify continued screening. In contrast, other BPSU studies have shown that there are not sufficient numbers of cases of congenital toxoplasmosis or neonatal herpes to justify national screening. More recently, clinicians reporting by obstetricians through the Royal College of Obstetricians and Gynaecologists, supplemented by paediatric reporting via the BPSU and unlinked anonymous HIV surveillance, has shown that HIV is prevalent throughout the UK. It is estimated that routine universal voluntary antenatal HIV testing would be cost effective for London and possibly elsewhere.

Active involvement of paediatricians

Every month the card arrives in the in-tray, and each paediatrician makes a decision—do I bother to complete it or do I throw it in the bin? Fortunately in over 90% of cases the decision is made to complete the card and return it to the BPSU office. To maintain this interest it is important that paediatricians are not overloaded with BPSU requests. The conditions under surveillance have to be relatively rare and only about 20% of paediatricians report any case in a year. On most occasions all the paediatrician has to do is tick a “nothing to report” box. This “negative” feedback is very important because it enables Richard Lynn, the Scientific Coordinator, to keep track of response rates and investigate the reasons that cards fail to return. It also helps us to estimate the extent to which there is under reporting of cases. The BPSU Executive Committee also tries to avoid overloading paediatricians by encouraging surveillance groups to make their questionnaires simple and short.

By choosing the right surveillance studies

The conditions on the surveillance card must be sufficiently important for paediatricians to want to make the effort. When a paediatrician ticks a box on the orange card, this results in a request for further information, usually in the form of a questionnaire to complete. In itself this is hardly an incentive to report cases! It must be clear to paediatricians that each surveillance project is likely to yield information that will be beneficial to children in general.

Active involvement of paediatricians

By saving effort

Coordination of activities facilitates the collection of information. Clinicians are approached by one Unit and are not put off by receiving questionnaires from many different sources. Investigators are helped by the BPSU to formulate and organise projects.

IS THE WORK OF THE BPSU WORTHWHILE?

The two most important criteria for acceptance of a study are:

1. That it attempts to answer a question of scientific importance
2. That the outcome of the study is of clear relevance to public health.

It is interesting to review some BPSU studies in the light of these criteria. They fall into a number of distinct groups as shown below, although some do not fit neatly into one or other category.

Infectious diseases

One of the first BPSU studies was of haemolytic uraemic syndrome (HUS). This remains a topical subject—another study of the same condition has now been completed. The recent study showed that most cases of HUS in the UK are caused by verocytotoxin producing E coli O157, and in spite of the impression given by the newspapers most cases are sporadic—outbreaks are uncommon. As HUS surveillance has been undertaken by several other national surveillance units it has been possible to make international comparisons.

The BPSU has provided data to help decide whether or not to perform national screening programmes for congenital infections. It was found that there were sufficient numbers of cases of transmissible syphilis and of congenital rubella to justify continued screening. In contrast, other BPSU studies have shown that there are not sufficient numbers of cases of congenital toxoplasmosis or neonatal herpes to justify national screening. More recently, clinicians reporting by obstetricians through the Royal College of Obstetricians and Gynaecologists, supplemented by paediatric reporting via the BPSU and unlinked anonymous HIV surveillance, has shown that HIV is prevalent throughout the UK. It is estimated that routine universal voluntary antenatal HIV testing would be cost effective for London and possibly elsewhere.

In order to determine whether or not children are developing variant Creutzfeldt–Jakob disease (vCJD), the study of progressive intellectual and neurological deterioration (PIND) in children was devised. There is good evidence that vCJD results from human exposure to beef products that contain abnormal prion protein. However, there is no useful screening test for vCJD at present, and detection of cases in children is complicated by the fact that there are many rare childhood neurodegenerative disorders. The strategy is therefore to

Abbreviations: BPSU, British Paediatric Surveillance Unit; CJD, Creutzfeldt–Jakob disease; HUS, haemolytic uraemic syndrome; MCAD, medium chain acyl coenzyme A dehydrogenase; PIND, progressive intellectual and neurological deterioration.
obtain clinical information about all children with PIND and present the anoma-
condition details to an Expert Group of paediatricians and neurologists. The Expert
Group carefully reviews the clinical picture and the investigations performed
locally and classifies the cases according to diagnosis. After five years of surveil-
lance 1320 children with suspected PIND have been reported to the study. It is
relatively reassuring that just six children with vCJD have been identified in
this age group, but they were all notified in the past three years. It is possible that
more cases of vCJD will occur in children, so PIND surveillance continues. It
would not be practical to perform this important public health surveillance
without the active cooperation of paediatricians via the BPSU.

Non-infectious conditions
An example of a study of a relatively rare condition that had widespread importance
was that of medium chain acyl coenzyme A dehydrogenase (MCAD) deficiency, in
which there is the possibility of a severe encephalopathy in susceptible children.
This condition might cause death after
encephalopathy in susceptible children.14
This condition might cause death after an
apparently minor illness, and this study highlighted the fact that MCAD deficiency
could be wrongly classified as sudden infant death syndrome. Another important differential diagnosis is Reye’s
syndrome, which is a rare non-inflam-
atory encephalopathy associated with hepatic dysfunction.

National surveillance for Reye’s syn-
drome was transferred to the BPSU card
in 1986 and was underway until 2001. This surveillance was able to document the
epidemic malignant care in incidence of
classic” Reye’s syndrome after the Commit-
tee on Safety of Medicines issued
warnings about the use of aspirin in
children.15 The study of MCAD deficiencyserved to highlight the fact that a number of metabolic disorders may present with a “Reye like” illness that is
clinically and pathologically similar to
Reye’s syndrome. Thus two BPSU studies shed light on each other and both helped
to illuminate an important public health
issue—the use of aspirin in young children.

Common disorders that are relatively uncommon in childhood
Big numbers (more than about 300 cases
a year) overload the BPSU reporting sys-
tem both for the paediatricians who fill
in the questionnaires and the surveil-
lance groups who gather the data. How-
ever, there have been two studies of the
epidemiology of diabetes in children,16 17
and more recently studies of inflam-
matory bowel disease,18 blindness,19 and (currently) stroke. Investigators have been able to focus on important ques-
tions about these conditions that are peculiar to childhood.

Physical and social surroundings
There have been studies of drowning20
and of fatal or severe reactions to food
ingestion.21 There have also been three

studies of various aspects of child abuse—Munchausen syndrome by proxy,17 subdural haemorrhage,20 and
more recently, acute abdominal injury in
the context of suspected child abuse. The
BPSU has provided a means of coordi-
nating and disseminating knowledge about these important and controversial
areas of child care.

Treatment
In the past there have been two studies of
haemolytic disease of the newborn,22 23
and a third is underway. These have been important because of the changing use of vitamin K prophy-
laxis in neonates. Because of the concern
that injected vitamin K might predispose
children to later malignancy, the routine
parenteral use of this vitamin has changed and there are now several schedules for oral administration. The most recent study of vitamin K defi-
ciency bleeding will be able to chart the
effects of changes in management. An-
other example has been the study of cer-
bral oedema and death associated with
diabetic ketoacidosis in children,24 and
the possible relation between these out-
comes and the treatment of children in
diabetic coma.

Vaccination
In view of the high profile concern about
the use of some vaccines in children, it is
perhaps surprising that there have only
been a couple of studies of problems
related to vaccination. Part of the diffi-
culty here is that vaccinations are given
to whole populations and therefore the
potential numbers for study are too large
for the BPSU system. However, there has
been a study of meningoencephalitis
associated with measles, mumps, and
rubella (MMR) vaccine.25 Furthermore,
the study of acute flaccid paralysis was
set up to ascertain whether or not polio
had been eradicated from the UK.26 The
BPSU has had meetings with the Medi-
cines Control Agency, the proposal being
that the BPSU system could be used to
target particular drugs and possibly vac-
cines. This is an area of potential future
development.

CONCLUSION
In the space available it is not possible to
give more than a flavour of the many
studies that have been carried out by the
BPSU. It can be seen that BPSU studies have answered important scientific ques-
tions and have made a significant contri-
bution to the health of children. Paedia-
tricians in the United Kingdom and Eire are
to be congratulated on all the work
that they have put into completing the

cards and questionnaires that make
BPSU studies possible. Hopefully this
review will inspire them to continue their active support for the work of their
Surveillance Unit.

Arch Dis Child 2002;87:269–271

.............

Authors’ affiliations
C Verity, Addenbrookes Hospital, Cambridge, UK (ex-chair, BPSU Executive Committee)
M Freeze, Institute of Child Health, London, UK (current chair, BPSU Executive Committee)
Correspondence to: Dr C M Verity, Child Development Centre, Box 107, Addenbrookes Hospital, Hills Rd, Cambridge CB2 2QG, UK, christopher.verity@addenbrookes.nhs.uk

REFERENCES
1 Anon. How the surveillance system works. In:
2 Taylor CM, Milford DV, Adak GK, et al. Haemolytic uraemic syndrome (HUS). In:
POSTCARD FROM DOWN UNDER

No smoke without ads?

Reading a British magazine imported into Australia I suddenly noticed the profusion of cigarette advertisements. Smoking advertising has been banned in Australia silver the early nineties and its abscence—the resolution a headache or the departure of an unwelcome guest—is refreshing but soon forgotten.

The BMJ Publishing Group has a whole journal, Tobacco Control, devoted to smoking and related issues. I’d recommend anyone with a social conscience and a sense of humour to read their editorial following Nottingham University’s acceptance of cash from British American Tobacco with which to establish a chair of International Business Ethics. Much research is published there and elsewhere, but I’d like to make a couple of observations from my time in Australia.

Firstly, it hasn’t been immediately obvious to me that fewer people are smoking. In fact, visitors from the UK feel that there are more, especially in restaurants, which may simply be a feature of outdoor cafe society where the need to segregate smokers is less keenly demanded.

Secondly, Australians seem less aware of when they were being exposed to cigarette advertising, although this may reflect my own (hyper aware) biases. My colleagues seem almost oblivious to cinema product placement and sponsorship of international sports like cricket and, if we believe the propaganda, the otherwise impoverished Formula 1 motor racing.

This leads to the third observation, which is that people seem unaware of product or brand-creep. Camel will always be a cigarette brand while they produce cigarettes, however trendy or well made the clothing. British American Racing will always be British American Tobacco with the interests of their paymasters at heart. Kraft products will now always be, essentially, a front for Phillip Morris, to the extent where some people regard them in the same light as Nestlé products in the eighties.

These are no reasons to allow tobacco advertising to recommence, quite the contrary. But they are a reason to think more broadly about how to combat the tobacco industry. We should never forget that we are dealing with organisations which are fighting for their corporate lives—if not those of their customers—and that they know how to fight. In the past the interesting point has been made that negotiation with the tobacco lobby is a mistake; we should simply legislate since they will, ultimately, listen to nothing less. (And, demonstrably, sometimes not even that). If we are taking these issues seriously we should look at media literacy as our strongest weapon—teaching people to understand the subtext and motives behind advertisements, as distinct from the actual message.

We need also to bear in mind the action/reaction dynamics in large multinationals. A third of a trillion dollar payout by the tobacco companies in the US is gratifying to us, and will hurt the industry, but it won’t worry too much while it has unregulated access to 2.3 billion potential customers in India and China alone. It will just shift its market, and then up the price slowly.

Whatever data eventually emerge from the gradual banning of tobacco advertising in the non USA developed world, we should ignore the industry’s fallacious arguments about advertising being aimed at brand shift rather than recruitment. It only takes a couple of neurones to do the sick maths the industry has done: if your product is killing 100 000 of your customers prematurely a year in the UK alone, and you want to sell the same number of cigarettes each year, you need to recruit the same number each year. Preferably this will be from the young—teenagers and early twenties—because they are busy with the business of forging a life and an identity. If you can trick them that smoking says something positive about themselves, and keep them smoking for long enough to get them addicted, then you’ve replaced one of your 100 000. You just need to do that every 20 minutes, for ever.

The advertising ban is a victory, and may it last forever, but it is only a small one in the context of a long, protracted, and dirty international war which we are a long way from winning. We should congratulate ourselves, and then ask which of our children they are going to recruit in the next twenty minutes, and the twenty minutes after that, and the twenty minutes after that...

I D Wacogne

Dr Wacogne was on secondment at the Royal Children’s Hospital, Brisbane for two years and is now completing his SpR training at the North Staffordshire Hospital, UK.